All About Multiple Sclerosis

More MS news articles for May 2003

Leading Swedish Biotechnology at BIO2003 in Washington

May 12, 2003
Stockholm, Sweden

The Swedish tradition of drug discovery and development is one of the strongest in the world. Following the growth of Pharmacia and AstraZeneca into global pharma companies, a new breed of companies is emerging. A number of the most successful companies will offer their research and technology to new partners, clients and investors at the BIO2003 Annual Convention and Exhibition in Washington, June 22-25.

Active Biotech

Active Biotech is seeking partnerships for a novel oral immunomodulatory drug (SAIK-MS) aimed the treatment of multiple sclerosis, as well as for an oral drug (TASQ) designed for the treatment of prostate cancer. The company is also seeking collaboration partners in relation to a novel concept (TTS) for immunotherapy of cancer.


Seeking partnerships with pharmaceutical companies for target identification and validation using Affibody's proprietary technology.


Bioventia is acting as a link between innovations, financing and competent management and is currently looking for international strategic partnerships.


Biovitrum is actively looking for in-licensing partners to strengthen the project portfolio in our core therapeutic areas: type 2 diabetes, obesity and oncology. Biovitrum also has expert knowledge and capabilities in process development and GMP manufacturing of recombinant protein drugs, which is offered to Biovitrum's partners and customers.

Global Genomics

Introducing Tangerine, a solution for gene expression profiling that identifies virtually all active genes in a given sample. The technology can be applied within drug discovery to support target and lead identification and validation through to analysis during clinical trials.

Karo Bio (Stockholm: KARO.ST - news)

Product opportunities are Selective GR modulators/ Anti-inflammatory therapeutics, Selective AR modulators/ Prostate cancer, Selective TR modulators, HRT, SERMs, Dxr compound series/ Antibacterial, IspB compound series/ Antibacterial, 10 Biokey(R) assays/ Antibacterial.

Melacure Therapeutics

Seeking partnerships with leading companies in therapeutic areas relevant to the melanocortin receptor field (MC1, MC3, MC4 and MC5) with opportunities in inflammation, obesity, diabetes and sexual dysfunction.


NeuroNova is seeking strategic partnerships with pharmaceutical and biotechnology companies with an international presence in order to further the clinical development and commercialisation of its innovative therapies within its Therapeutic Neurogenesis and its Cell Transplantation Therapy programs.

The press release in PDF format can be downloaded from the following link.

Copyright © 2003 Yahoo! Inc.